The Top 25 Voices in Precision Medicine announced by BIS Research

The Top 25 Voices in Precision Medicine was announced today, representing an initiative by BIS Research and Insight Monk to recognize the work of thought leaders in the field of precision medicine at a global stage.

The nomination-based compendium showcases and celebrates the diversity and talent among the interdisciplinary leaders of the healthcare industry and highlights their influence in the field.

This compendium has been compiled by the efforts of the BIS Research executive team, who had spread the word about it to individuals across the globe with significant contributions to the healthcare industry. More than six months of nominee profile form-filling resulted in 200-plus nominations from across the global healthcare industry.

The list was selected based on the assessment of the aggregate impact score that a person contributes to the advancement of the precision medicine ecosystem.

IMPACT

Success in driving growth in the field of precision medicine has been largely dependent on the presence of thought leaders who are highly skilled interdisciplinary leaders, contributing their innovation, organization and guidance. These leaders, with their "voice," have been able to influence and benefit the healthcare industry, according to BIS.

The list contains a host of individuals from corporate settings as well as academia. Gianluca Pettiti, president biosciences, Thermo Fisher Scientific, one of the Top 25 Voices, focuses on precision medicine to create an improvised diagnostic system for doctors so they can make better choices, resulting in patients having better outcomes.

Another thought leader of Top 25 Voices from the corporate domain is Jennifer Cook, CEO of Grail Inc., who believes that in this period of rapid evolution, there's an unprecedented opportunity to improve health outcomes. Individuals from leading medical schools such as Stanford University and Harvard Medical School represent the academicians in the Top 25.

Of the nominees that responded, 61 percent felt oncology will be the major breakthrough area for precision medicine in the next few years, compared to only 20 percent who felt infectious diseases would claim that throne.

Among those, 55 percent felt the legal and regulatory framework will be the major challenge for precision medicine. Just 15 percent said the lack of partnerships will be a major challenge.

The full list:

• Emily LeProust, Twist Bioscience
• Eric Dishman, National Institute of Health
• Eric S. Slander, Broad Institute
• Eric Topal, Scripps Research Institute
• Fabric Andre, Institute Gustav Roussy
• Francis S. Collins, National Institute of Health
• George Asimenos, DNAnexus
• George Church, Harvard Medical School
• George D. Yancopoulos, Regeneron Pharmaceuties, Inc.
• Gianluca Pettiti, Thermo Fisher Scientific
• Jennifer Cook, GRAIL, Inc.
• John Giannios, International Association of Perioperative Medicine and Nanosurgery
• Kamal Obbad, Nabula Genomics
• Kfir Oved, MeMed Dx
• Kristine Achcraft, YouScript
• Leena Gandhi, Eli Lilly and Company
• Michael J. Pellini, Section 32
• Peer Schatz, QIAGEN
• Razelle Kurzrock, University of California, San Diego Moores Cancer Center
• Robertt Green, Harvard Medical School
• Ryan Spitler, Stanford University School of Medicine
• Sarafim Batazoglou, Illumina
• William Pao, F. Hoffman-La Roche AG
• John Halamka, Beth Israel Deaconess Medical Center
• Alex Dickinson, ChromaCode, Inc.

THE TREND

In a 2018 HIMSS study, eight out of 10 healthcare leaders said precision medicine was a priority for their organizations. Precision medicine affords the possibility of making personalized medicine more actionable, bolstering population health efforts and ultimately reducing costs.
 

Twitter: @JELagasse

Email the writer: jeff.lagasse@himssmedia.com